Infectious Disease Control
Releases published in the last 30 days. 
Page 1 of 1
- Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
- 12/8/2025 1:10:34 PM
- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that new data evaluating XOSPATA™ (gilteritinib) across FMS-like tyrosine kinase 3 mutation-positive (FLT3m+) acute myeloid leukemia (AML), including in relapsed or refractory (R/R), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming American …
- Breakthrough Accessibility Initiative: THMT Research Now Available to Global Audiences
- 12/8/2025 8:00:00 AM
- We’re excited to announce Telehealth and Medicine Today (THMT) and CACTUS AI Solutions are bringing cutting edge telehealth and AI research to practitioners, policymakers, and patients around the globe! Selected articles are now enhanced with: Multilingual Access - Full translations and summaries in Chinese, German, Spanish, and English.
- Mitigating Exposures to Cladosporium and Other Microbial Contaminants in the Built Environment
- 12/3/2025 9:22:14 PM
- There are numerous species of Cladosporium. They produce various colors of fungal colonies that can appear as olive, brown, or black. Naturally occurring Cladosporium spores in the outdoor environment are present year-round in many parts of the country.
- Stand Up To Cancer 2025 launches moving Tribute Mile to honour lives lost to cancer
- 11/26/2025 10:39:12 AM
- • Stand Up To Cancer will unite people across the UK in December with a powerful moment of remembrance, the Stand Up To Cancer Tribute Mile. • This mile-long installation of over 5,000 illuminated lanterns will honour those who have lost their lives to cancer.
- Particles that enhance mRNA delivery could reduce vaccine dosage and costs
- 11/10/2025 9:06:58 AM
- A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine dose. In studies in mice, the researchers showed that an mRNA influenza vaccine delivered with their new lipid nanoparticle could generate the same immune response as mRNA delivered by nanoparticles made with FDA-approved materials, but at around 1/100 …
- « Previous
- 1
- Next »